Research · PMID 41403046
Reviewed by Neal Rouzier, MD, Preventive Medicine · Sep 2026
Relationship between 10- and 30-year PREVENT Risk Scores with Coronary Artery Calcium and Incident Atherosclerotic Cardiovascular Disease: MESA.
European journal of preventive cardiology · December 2025 · Rishi Rikhi, Haiying Chen, John Jeffrey Carr, Michael D Shapiro, Alain G Bertoni
What this study found
AIMS: The 2023 American Heart Association Predicting Risk of Cardiovascular Disease (CVD) EVENTs (PREVENT) risk equations allow for 10- and 30-year atherosclerotic CVD (ASCVD) quantitative risk assessment. We investigated the relationship between PREVENT 10-year and 30-year ASCVD risk categories with coronary artery calcium (CAC) and incident ASCVD.
How RAGMD uses this study
Clinical questions this paper informs
Synthesis lives on the evidence question — this page shows where the study sits in that analysis.
Primary study
Should coronary artery calcium scoring guide statin decisions?
Coronary artery calcium can reclassify intermediate-risk patients and inform statin initiation when risk is uncertain. A score of zero may support deferring therapy in selected low-risk individuals with shared decision-making.
Open evidence analysisSupporting literature
Is ApoB more useful than LDL-C for cardiovascular risk prediction?
Prospective cohorts and meta-analyses suggest ApoB may capture atherogenic particle burden better than LDL-C alone, particularly when triglycerides are elevated or LDL particles are discordant with LDL-C.
Open evidence analysisSupporting literature
Should adults take statins for primary cardiovascular prevention?
Meta-analyses of primary prevention trials show reduced major adverse cardiovascular events with statins in appropriately selected moderate-to-high-risk adults. Shared decision-making should weigh absolute risk reduction against side effects and patient preference.
Open evidence analysisSupporting literature
Does elevated lipoprotein(a) independently increase cardiovascular risk?
Mendelian randomization and epidemiologic data support Lp(a) as a causal cardiovascular risk factor. Specific Lp(a)-lowering therapies are emerging but routine treatment beyond standard risk factor control awaits outcome trial confirmation.
Open evidence analysisSupporting literature
Do therapies that raise HDL reduce cardiovascular events?
Trials of niacin and CETP inhibitors raised HDL without consistent reduction in cardiovascular events when added to statins, challenging the hypothesis that raising HDL alone is protective.
Open evidence analysis